Apixaban in Atrial Fibrillation

8th March 2013 by Louise Hudman

This guidance is another new drug for the use in AF as an anticoagulant. It is a Factor Xa inhibitor and is more effective than warfarin. It hasn’t been shown to be more effective than Rivaroxaban and Dabigatran. It has the lowest bleeding risk. As always, we should wait for local prescribing advice before using.

It can be considered if the patient has non-valvular AF and at least 1 of:

  • Prior stroke or TIA
  • 75 or older
  • Hypertension
  • Diabetes
  • Symptomatic heart failure

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I have found LocumDeck to be the most helpful and invaluable resource for keeping bookings and accounts. I want to thank you for the wonderful service you provide. Many thanks once again for all the NASGP provides, and particularly for use of the excellent resource LocumDeck has proved to be – something I have recommended to many colleagues who have taken a step to locum work."

Dr Ruth Snowball

Dr Ruth Snowball

See the full list of features within our NASGP membership plans

Membership